What vasoactive intestinal peptide is
Vasoactive intestinal peptide, often shortened to VIP, is a naturally occurring peptide that has been studied across a range of clinical contexts. No approved product label information is available in this record, so its official drug class, mechanism of action, and approved indications cannot be summarized here.
What the evidence shows
There are 62 registered clinical trials involving this compound. Sampled studies span varied areas of interest, including an ovarian innervation study in patients with polycystic ovary syndrome (status unknown), a phase 4 trial examining combined general anesthesia and bilateral paravertebral block in off-pump coronary artery bypass surgery (status unknown), and a phase 2/phase 3 trial of combination chemotherapy and bevacizumab in patients with advanced neuroendocrine tumors, which was terminated.
FAQ
No approved product label is reflected in this record. The available data here consists of clinical trial registrations rather than an approved drug label.
There are 62 registered clinical trials involving this compound. These trials span a range of research areas rather than a single approved use.
Sampled trials include research on ovarian innervation in polycystic ovary syndrome, anesthesia approaches during coronary artery bypass surgery, and chemotherapy combinations for advanced neuroendocrine tumors. One of these trials was terminated, while the status of others is listed as unknown.
No side effect report data is available in this record, so reported reactions cannot be summarized here.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: ClinicalTrials.gov
Updated 2026-11-07